Key result
Reldesemtiv binding to the fast skeletal troponin complex potentiates troponin C compacting with a total free binding energy of -41.30 kcal/mol, potentially favoring the slow release of calcium ions.
Why the study?
Small molecules activating fast skeletal muscle troponin complex to treat muscle weakness in neuromuscular diseases have faced off-target effects, leading to the development of the second-generation activator Reldesemtiv.
Computational modeling reveals that Reldesemtiv binds to the fast skeletal troponin complex, promoting conformational changes that may sensitize the subunit to calcium and increase muscle strength.
May support troponin-targeted muscle activation in neuromuscular disease models; leaves open clinical translation.
Muscle weakness as a secondary feature of attenuated neuronal input often leads to disability and sometimes death in patients with neurogenic neuromuscular diseases. These impaired muscle function has been observed in several diseases including amyotrophic lateral sclerosis, Charcot-Marie-Tooth, spinal muscular atrophy and Myasthenia gravis. This has spurred the search for small molecules which could activate fast skeletal muscle troponin complex as a means to increase muscle strength. Discovered small molecules have however been punctuated by off-target and side effects leading to the development of the second-generation small molecule, Reldesemtiv. In this study, we investigated the impact of Reldesemtiv binding to the fast skeletal troponin complex and the molecular determinants that condition the therapeutic prowess of Redesemtiv through computational techniques. It was revealed that Reldesemtiv binding possibly potentiates troponin C compacting characterized by reduced exposure to solvent molecules which could favor the slow release of calcium ions and the resultant sensitization of the subunit to calcium. These conformational changes were underscored by conventional and carbon hydrogen bonds, pi-alkyl, pi-sulfur and halogen interactions between Reldesemtiv the binding site residues. Arg113 (-3.96 kcal/mol), Met116 (-2.23 kcal/mol), Val114 (-1.28 kcal/mol) and Met121 (-0.63 kcal/mol) of the switch region of the inhibitory subunit were among the residues that contributed the most to the total free binding energy of Reldesemtiv highlighting their importance. These findings present useful insights which could lay the foundation for the development of fast skeletal muscle small molecule activators with high specificity and potency.
No takes yet. Share an insight, caveat, or question.
Issahaku et al. (2023) studied Impaired muscle function (e.g., amyotrophic lateral sclerosis, spinal muscular atrophy). Reldesemtiv vs. Unbound fast skeletal troponin complex was evaluated on Total binding free energy (ΔG bind). Reldesemtiv binding to the fast skeletal troponin complex potentiates troponin C compacting with a total free binding energy of -41.30 kcal/mol, potentially favoring the slow release of calcium ions.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: